

## 8.R&D Pipeline



	Stage	Theme	Region*	Dosage Form	Characteristics	Next Step
1	Approved	HARUROPI <sub>®</sub> PATCH (Haruropi <sub>®</sub> Tapes)	Asia	Patch	Parkinson's disease	To be launched In FY25
2	Approved	APOHIDE <sub>®</sub> LOTION 20%	Asia	Lotion	Primary palmar hyperhidrosis	To be launched In FY2025
3	Approved	APOHIDE <sub>®</sub> LOTION 20%	Oceania	Lotion	Primary palmar hyperhidrosis	To be launched In FY2026
4	Approved	ZICTHORU <sub>®</sub>	Oceania	Patch	Chronic pain associated with cancer, Chronic pain with inflammatory component	To be launched In FY2026
5	Phase3	TH-004	JPN	Gel	Postherpetic neuralgia	Phase 3 Topline data in FY2026
6	Phase3 being prepared	HP-3150US	North America	Patch	Chronic low back pain	Phase 3 start in FY2026
7	Phase3	HP-6050	JPN	Microneedle	Delirium, Psychomotor agitation and Irritability	Phase 3 Topline data in FY2027

<sup>\*</sup>Parts highlighted in yellow indicate changes from the previous announcement made on July 10<sup>th</sup>, 2025.